Form 8-K Roivant Sciences Ltd. For: Apr 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
JPMorgan's Take on Roivant Sciences (ROIV) Buyback and Positive Data Annoucement
April 2, 2024 8:08 AM EDTJPMorgan analyst Brian Cheng reiterated an Overweight rating on Roivant Sciences (NASDAQ: ROIV).
The analyst comments "Before market open this morning, Roivant announced up to a $1.5bn stock buyback program and positive top-line data from its Ph 2 NEPTUNE brepocitinib study in... More
Truist Securities sees Roivant Sciences (ROIV) shares up today on positive brepocitinib data
April 2, 2024 8:04 AM EDTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $23.00 price target on Roivant Sciences (NASDAQ: ROIV), saying positive brepocitinib data supports potential success in NIU.
The analyst commented, "We believe Roivant shares could be up today following announcement of positive Ph2 results for... More
